Tvardi Therapeutics, Inc.
TVRDTvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.
- Revenue
- +20.3%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.
Follow TVRD
Alert me
Tvardi Therapeutics, Inc. (TVRD) Return on invested capital
Tvardi Therapeutics, Inc.'s return on invested capital over the twelve months to Sep 30, 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −421.8% (fiscal 2022) to 4.69% (fiscal 2020); the current reading is higher than 91% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 421.75 |
| FY2022 | −421.8% | (332.53) |
| FY2021 | −89.2% | (93.91) |
| FY2020 | 4.69% | 203.78 |
| FY2019 | −199.1% | (199.09) |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| TVRD Tvardi Therapeutics, Inc. | 0.00% |
| GUTS Fractyl Health, Inc. compare | 0.00% |
| ACTU Actuate Therapeutics, Inc. compare | 0.00% |
| DYAI Dyadic International Inc. compare | 0.00% |
| JSPR Jasper Therapeutics, Inc. compare | 0.00% |
| QNTM Quantum Biopharma Ltd. compare | 0.00% |
| CASIF CASI Pharmaceuticals Inc. compare | 0.00% |
| BOLT Bolt Biotherapeutics, Inc. compare | −154.8% |
| NEUP Neuphoria Therapeutics Inc. compare | −186.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.06% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)